Last week’s Aduhelm coverage decision by the Centers for Medicare and Medicaid Services (CMS) raises the bar for three other antiamyloid antibodies in late-stage development: Eisai’s and Biogen’s lecanemab, Eli Lilly’s donanemab and Roche’s gantenerumab. It all depends on the evidence that the drugmakers provide in their submissions to the FDA.
Source: Drug Industry Daily